The use of antithrombotics in patients presenting with stroke and atrial fibrillation

Therapeutics and Clinical Risk Management

Volumn 3, Issue 3, 2007, Pages 491-498

  Burgess, Carl ^a   Ingham, Tristram ^a   Woodbridge, Martin ^b   Weatherall, Mark ^a   Nowitz, Michael ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Medsafe New Zealand   (New Zealand)

Author keywords

Aspirin; Atrial fibrillation; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; ALCOHOL ABUSE; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG WITHDRAWAL; ETHNICITY; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PEPTIC ULCER; PRACTICE GUIDELINE; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK;

EID: 34547660698     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Adams Jr HP, Bendixen BH, Kappelle J, et al. 1993. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke, 24:35-41.
2. Atrial Fibrillation Investigators 1994. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials Am Intern Med, 154:1449-57.
3. Bungard TJ, Ghali WA, Teo KT, et al. 2000. Why do patients with atrial fibrillation not receive warfarin? Am Intern Med, 160:41-6.
4. DiMarco JP, Flaker G, Waldo AL, et al. 2005. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) Study. Am Heart J, 149:650-6.
5. [EAFT] European Atrial Fibrillation Trial Study Group. 1993. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet, 342:1255-62.
6. Evans A, Perez I, Yu G, et al. 2000. Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. Stroke, 32:2106-11.
7. Evans A, Perez I, Yu G, et al. 2001. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation. Stroke, 32:2828-32.
8. Gage BF, Boechler M, Doggette AL, et al. 2000. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke, 31:822-7.
9. Gage BF, van Walraven C, Pearce L, et al. 2004. Selecting patient with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. Circulation, 110:2287-92.
10. Gage BF, Waterman AD, Shannen W, et al. 2001. Validation of clinical classification schemes for predicting stroke. Researchers from the National registry of atria] fibrillation. JAMA, 285:2864-70.
11. Gardiner C, Williams K, Mackie IJ, et al. 2004. Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. Brit J Hematology, 128:242-7.
12. Go AS, Hylek EM, Chang Y, et al. 2003. Anticoagulation therapy for stroke prevention in atrial fibrillation. How well do randomized trials translate into clinical practice? JAMA, 290:2685-92.
13. Gullov AL, Koefoed BG, Petersen P, et al. 1998. Fixed mini dose warfarin and aspirm alone and in combination versus Austed-dose warfann for stroke prevention in atnal fibrillation; 2nd Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation Study. Arch Intern Med, 158:1513-21.
14. Hart RG, Halperin JL. 1999. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Am Intern Med, 131:688-95.
15. Hart RG, Pearce LA McBride R, et al. 1999. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke, 30:1223-29.
16. Hart RG, Pearce LA, Miller VJ, et al. 2000. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the Stroke Prevention in Atrial Fibrillation Studies. Cerebrovasc Dis, 10:39-43.
17. Hatano S. 1976. Experience from a multicenter stroke register a preliminary report. Bull WHO, 54:541-53.
18. Hylek EM, Go AS, Chang Y, et al. 2003. Effect of intensity of all anticoagulation on stroke seventy and mortality in atrial fibrillation. N Engl J Med, 349:1019-26.
19. International Statistical Classification of Diseases. 2000. Related health problems. 10th Review, Australian modification. Vol.1-5. Copyright of Commonwealth of Australia.
20. Iqbal MB, Taneja AK, Lip GYH, et al. 2005. Recent developments in atrial fibrillation. BMJ, 330:238-43.
21. Jackson SL, Peterson GM, Vial, Jupe DML. 2004. Improving the outcomes of anticoagulation: An evaluation of home follow-up of warfarin initiation. J Int Med, 256:137-44
22. Koudstraal PJ. 2000. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2:CD000187.
23. Laguna P, Martin A, del Arco C, et al. 2004. Risk factors for stroke and thromboprophylaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-I Study. Ann Emerg Med, 44:3-11.
24. Laupacis A, Albers G, Dalen J, et al. 1998. Antithrombotic therapy in atrial fibrillation. Chest, 114(suppl):5795-895.
25. Lip GYH, Boos CJ. 2006. Antithrombotic treatment in atrial fibrillation. Heart, 92:155-61.
26. Miller VT, Rothrock JF, Pearce LA, et al. 1993. Ischemic stroke in patients with atrial fibrillation. Effect of aspirin according to stroke mechanism. Neurology, 43:32-6.
27. Morocutti C, Amabile G, Fattapposta F, et al. 1997. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke, 28:1015-21.
28. Murray E, Fitzmaurice D, McCahon D, et al. 2004. Training for patients in a randomized control trial of self management of warfarin treatment. BMJ, 328:437-8.
29. Perez-Gomez F, Alegria E, Berjǒn J, et al. 2004. Comparative of antiplatelet, anticoagulant, or combined therapy in patients with valvular and non valvular atrial fibrillation. J Am Coll Cardiol, 44:1557-66.
30. Petersen P, Boysen G, Godtfredsen J, et al. 1989. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The copenhagen AFASAK study. Lancet, i;175-9.
31. Stroke Prevention in Atria] Fibrillation III Investigators. 1996. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrilliation. Lancet, 348:633-8.
32. Stroke Prevention in Atrial Fibrillation Investigators. 1991. The stroke preventions in atrial fibrillation study: final results. Circulation, 84:527-39.
33. Stroke Prevention in Atrial Fibrillation Investigators. 1996. Bleeding during anti-thrombotic therapy in patients with atrial fibrillation. Arch Intern Med, 156:409-16.
34. Sudlow M, Thomson R, Thwaites B, et al. 1998. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet, 352:1167-71
35. Taylor FC, Cohen H, Ebrahim, S. 2001. Systemic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ, 322:321-6.
36. Tennant A, Geddes JM, Chamberlain MA. 1996. The Barthel Index an ordinal score or interval level measure. Clin Rehab, 10:301-8.
37. Wang TK, Massaro JM, Levy D, et al. 2003. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. JAMA, 290:1049-56.